This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Zdravka Medarova, PhD
Founder and Chief Technology Officer at TransCode Therapeutics
Speaker

Profile

Zdravka Medarova, PhD has served as Scientific Co-founder and a member of the advisory board of TransCode since January 2016. Dr. Medarova has been on the Faculty of Harvard Medical School and MGH since Jne 2007. She has served as an Associate Professor of Radiology at Harvard Medical School from April 2016 and as an Assistant in neuroimaging at the Athinoula A. Martinos Center for biomedical Imaging at MGH since June 2007. Dr. Medarova joined TransCode fulltime as the Chief Technology Officer on October 1, 2021. Dr. Medarova is a geneticist/ cancer biologist by training and is internationally recognized for her work on non-coding RNA for cancer therapy. She is one of the first to describe the design and application of nanoparticles as carries of siRNA to tumors. Dr. Medarova obtained a B.A. in pre medicine from the University of South Maine in September 1998 and a Ph.D. in Genetics from the University of New Hampshire in December 2001.

Agenda Sessions

  • Research and Development of the Template-Directed RIG-I Agonist, TTX-RIGA, for Systemic Cancer Immunotherapy

    09:20